Kairos Pharma, Ltd.

KAPA · AMEX
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$2,603-$1,812-$1,050-$2,145
Dep. & Amort.$160$160$160$98
Deferred Tax$0$0$0$0
Stock-Based Comp.$218$913$0$300
Change in WC-$1,984$764$129$1,191
Other Non-Cash$254$56$408$144
Operating Cash Flow-$3,955$81-$353-$412
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0-$109
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0-$109
Financing Activities
Debt Repay.$0$0$895$330
Stock Issued$5,524-$425-$57$250
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$390$0-$121$0
Financing Cash Flow$5,134-$425$717$580
Forex Effect$0$0$0$0
Net Chg. in Cash$1,179-$344$364$59
Supplemental Information
Beg. Cash$93$437$73$14
End Cash$1,272$93$437$73
Free Cash Flow-$3,955$81-$353-$412